Last updated: March 3, 2026
What is NDC 00781-5515?
NDC 00781-5515 corresponds to Glatiramer Acetate (generic of Copaxone), used to treat multiple sclerosis (MS). It is produced by Teva Pharmaceuticals and other generic manufacturers. The drug traditionally sells at a high price point in the U.S., with significant market share in MS therapy.
Market Size and Competitive Landscape
Historical Sales Data
- In 2022, the U.S. market for MS therapies was valued at approximately $9 billion, with Glatiramer Acetate accounting for roughly $1.2 billion (IQVIA, 2023).
- Originator brand Copaxone generated $600 million in U.S. sales, with generics capturing film of the overall market.
Competition
- Several generics entered the market post-patent expiry in 2015.
- Major competitors include Teva, Mylan (now Viatris), and Sandoz.
- Biosimilar options are limited due to the complex nature of the molecule, but recent regulatory approvals may introduce additional players.
Regulatory Status
- First generic approval granted in 2015 by FDA.
- Multiple biosimilar and generic versions have been approved in the past five years, increasing market competition and price erosion.
Pricing Dynamics
Current Price Range
- Retail price (wholesale acquisition cost, WAC) for a 20 mg/mL prefilled syringe:
- Brand (Copaxone): ≈ $7,500 per 30-day supply.
- Generics (such as NDC 00781-5515): range $3,500–$4,500 per 30-day supply (IQVIA, 2023).
Price Trends
- Generic entry initially caused a sharp decline in price, approximately 40–50% reduction within two years of market entry.
- Prices have stabilized but remain below the brand.
- Competition among generic manufacturers maintains downward pressure.
Market Projections
Short-term (Next 2 Years)
- Growth expected to be modest as initial generic market penetration nears saturation.
- Price erosion of 5–10% annually as generic competition intensifies.
- Market share for NDC 00781-5515 projected to hold around 15–20% of the total MS injectable market.
Long-term (Next 5 Years)
- With the advent of biosimilars and patent extensions possibly expiring, new entrants may further depress prices.
- Projected average price of a 30-day supply could decline to $2,500–$3,000.
- Total sales volume may decline slightly as new therapies, oral agents, and bi-specific monoclonal antibodies gain market share.
Key Factors Influencing Price and Market
- Patent litigations and settlements influencing market entry.
- Regulatory approvals of biosimilars, which could impact market share.
- Changes in healthcare policies regarding drug reimbursement and formulary placement.
- Introduction of alternative MS treatments (e.g., oral agents like Mavenclad) that may cannibalize injectable therapy sales.
Regulatory and Policy Impact
- The FDA has prioritized biosimilar development, which could lead to additional competition.
- CMS reimbursement policies favor generic therapies, likely accelerating price reductions.
- State-level pharmacy benefit managers (PBMs) may negotiate further discounts or prefer alternative therapies to reduce costs.
Risks and Uncertainties
- Patent litigation delays for biosimilars.
- Potential supply chain disruptions impacting manufacturing costs.
- Shifts in clinical guidelines favoring novel oral therapies.
- Evolving reimbursement landscape affecting provider prescribing behavior.
Key Takeaways
- NDC 00781-5515 is a key generic for MS, with a market share of about 15–20% of the MS injectable market.
- Prices have declined over the past five years from approximately $7,500 to an estimated $3,500–$4,500 per 30-day supply.
- Market saturation and biosimilar competition are expected to drive prices lower, possibly below $3,000 within five years.
- The overall market size for Glatiramer Acetate in the U.S. will likely decrease slightly as newer therapies gain prominence.
FAQs
1. What factors could slow down price declines for NDC 00781-5515?
Patent disputes, supply constraints, or slower-than-expected biosimilar approval processes could preserve higher prices longer.
2. How does the emergence of biosimilars impact the market?
Biosimilars can increase competition, reduce prices further, and potentially capture a significant market share, pressuring existing generics.
3. Are there alternative therapies likely to replace Glatiramer Acetate?
Yes. Oral MS agents like Mavenclad and newer monoclonal antibodies may reduce demand for injectable therapies.
4. What is the pace of generic market share growth?
It has been steady since 2015, reaching around 15–20%, with growth plateauing as the market becomes saturated.
5. How do healthcare policies influence pricing?
Reimbursement reforms, PBM negotiations, and formulary preferences tend to favor lower-cost generics, accelerating price declines.
References
[1] IQVIA. (2023). Retail Prescription Drug Trends.
[2] U.S. Food and Drug Administration. (2015). Approval of Generic Glatiramer Acetate.
[3] Centers for Medicare & Medicaid Services. (2022). Drug Pricing and Reimbursement Policies.
[4] Statista. (2023). Multiple Sclerosis Market Overview.
